A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain

Israeli CLL Study Group

نتاج البحث: نشر في مجلةمقالةمراجعة النظراء

5 اقتباسات (Scopus)

ملخص

Background: Chronic lymphocytic leukemia (CLL) is frequently accompanied by immune dysregulation. Aims: In this multicenter prospective study, we investigated whether heavy + light chains (HLC: IgGκ, IgGλ, IgAκ, IgAκ, IgMκ, IgMλ) and IgG subclasses (IgG1, IgG2, IgG3, and IgG4) could be used as novel prognostic markers of immunoparesis in 105 treatment-naïve patients with CLL. Results: Heavy + light chains immunoparesis of ≥1, ≥2, and ≥3 isotypes was evident in 74 (70%), 58 (55%), and 36 (34%) patients, respectively. Severe HLC immunoparesis was identified in 40 (38%) patients. Of the IgG subclasses, IgG1 and IgG2 were most frequently suppressed, affecting 46 (44%) and 36 (34%) patients, respectively; 63 (60%) patients had low levels of at least one IgG subclass. In multivariate analysis, severe HLC immunoparesis (hazard ratio [HR]: 36.5; P =.010) and ΣFLC ≥ 70 mg/L (HR: 13.2; P =.004) were the only factors independently associated with time to first treatment (TTFT). A risk model including these variables identified patients with 0, 1, and 2 risk factors and significantly different TTFT (P <.001). Patients with two factors represented an ultra-high-risk group with a median TTFT of only 1.3 months. Conclusion: The above findings demonstrate the potential for the use of HLC immunoparesis, together with sFLC measurements, as future prognostic biomarkers in CLL.

اللغة الأصليةالإنجليزيّة
الصفحات (من إلى)335-341
عدد الصفحات7
دوريةEuropean Journal of Haematology
مستوى الصوت103
رقم الإصدار4
المعرِّفات الرقمية للأشياء
حالة النشرنُشِر - 1 أكتوبر 2019
منشور خارجيًانعم

بصمة

أدرس بدقة موضوعات البحث “A new risk model to predict time to first treatment in chronic lymphocytic leukemia based on heavy chain immunoparesis and summated free light chain'. فهما يشكلان معًا بصمة فريدة.

قم بذكر هذا